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Serum Cathepsin B (CB) is prognostic and may predict response 
to therapy in chemotherapy-naive PS2 advanced NSCLC patients 
treated on two concurrent phase III trials of paclitaxel poliglumex 
(PPX) vs control treatments (STELLAR 3 and 4)
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Background: STELLAR 3 and 4 are concurrently run phase III trials 
of ﬁrst-line PPX vs standard therapy for patients meeting identical en-
try criteria. Patients all had performance status 2 and had stage IIIB/IV 
or recurrent NSCLC without prior chemotherapy. Combined analysis 
identiﬁed estrogen as both prognostic and predictive of response to 
PPX in women on the two trials. CB is an estrogen-regulated lyso-
somal cysteine protease produced by cancer cells and tumor-associated 
macrophages. This peptidase is prognostic in several epithelial cancers 
and is the predominant metabolizing enzyme for paclitaxel poliglumex 
(PPX). Estrogen-mediated elevation of CB appears to mediate PPX 
activity against human tumor xenografts in mice (Di Giovine, et. al., 
European Journal of Cancer Supplements, Volume 4, No.12, page 191, 
2006) and is postulated to explain the differential response to PPX in 
pre and post-menopausal women. To investigate this hypothesis, we 
analyzed CB levels in serum samples from STELLAR 3 and 4 study 
patients and correlated results with survival.
Methods: Pretreatment serum samples were analyzed from 450 
patients (STELLAR 3, n=315; STELLAR 4, n=135). STELLAR 3 
patients received doublet chemotherapy (carboplatin with either PPX 
or paclitaxel) while STELLAR 4 patients received singlet therapy 
(PPX or investigator’s choice of gemcitabine or vinorelbine). Serum 
was assayed for CB by highly speciﬁc ELISA (ICON labs). Patients 
were categorized as high or low CB based on whether their values were 
above or below the breakpoint seen at the median value (64 ng/ml). 
Correlation of CB with survival was evaluated by log rank for pooled 
patients from the two studies. 
Results: Analysis by treatment arm: median survival (MS) was worse 
for patients with high CB on the control arms of STELLAR 3 and 
4. For non-PPX treated patients, if CB was above 64 ng/ml MS was 
174 days compared to 234 days for patients with CB at or below 64 
ng/ml (HR 1.36, P=.022). For patients treated with PPX, this survival 
disadvantage for high CB was not seen (MS 220 vs 249 days, HR 0.96, 
P=.82). Analysis by CB level: patients with high CB exhibited a trend 
in favor of improved survival with PPX compared to control treatments 
(MS 220 vs 174 days, HR 0.80, P=.13). Patients with CB 64 ng/ml or 
less had similar survival whether treated with PPX or control treat-
ments (249 vs 234 days, HR 1.12, P=.474).
Conclusions: Serum CB appears to be a prognostic biomarker for 
NSCLC with inferior survival in patients with high levels. CB may 
also be predictive of response to targeted paclitaxel in the form of PPX 
based on retrospective analysis of STELLAR 3 and 4. Analysis of se-
rum CB should be built in to prospective trials and could be considered 
as a stratiﬁcation factor for future studies of PPX.
Novel Therapeutics: Immunotherapy/Vaccines
P3-020 NT: Immunotherapy/Vaccines Posters, Wed, Sept 5 – Thur, Sept 6 
Combined CCL19/IL-7 treatment eradicates tumors in murine 
models of lung cancer
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Background: Effective anti-tumor responses require both antigen pre-
senting cells and lymphocyte effectors. Although lung cancers express 
tumor antigens, they are ineffective as antigen presenting cells because 
tumor cells often have limited expression of MHC Ags and lack co-
stimulatory molecules.
It has been demonstrated that local and systemic administration of 
chemokines or cytokines as stimulators of the immune response is 
beneﬁcial as potent anti-cancer strategy. Epstein Barr virus-induced 
molecule 1 ligand chemokine (ELC/CCL19) is a CC chemokine that 
strongly chemoattracts both dendritic cells (DC) and T lymphocytes. 
Interleukin-7 (IL-7) ampliﬁes the longevity of the tumor antigen spe-
ciﬁc T cells and NK effectors. In this study we evaluated the anti-tumor 
efﬁcacy of combined CCL19/IL-7 treatment in two murine lung cancer 
models.
Methods: 105 L1C2 and 3LL cells have been injected into the right 
ﬂank of Balb/C and C57/Bl6 mice respectively. Five days after injec-
tion mice have been treated intratumorally with injection of recombi-
nant ELC/CCL19 (0.5μg/dose) three times per week and Interleukin 
7 (200ng/dose) daily for 2 weeks. For the evaluation of anti-tumor 
responses, tumors were harvested three weeks after combined treatment 
and assessed for H&E staining to analyze tumor inﬁltrating T cell sub-
sets by ﬂow cytometry. Tumors were evaluated for the production of 
IL-10, IL-12, GM-CSF, IFNγ, TGFβ, by ELISA and PGE2 by enzyme 
immunoassay (EIA) in the supernatants after an overnight culture.
Results: In the C57/Bl6 mice there was a dramatic inhibition of tumor 
growth compared to diluent treated controls, in 5 out of 6 Balb/C mice 
we even observed a complete tumor eradication. Flow cytometric 
analysis showed a signiﬁcant increase in both CD4 and CD8 subsets as 
well as dendritic cells. However, there was a decrease in CD4+CD25+ 
T regulatory cells in the tumor inﬁltrating lymphocytes of combined 
treated mice. Tumor tissue cytokine proﬁles showed a shift towards 
immunostimulatory molecules.
Conclusions: Combination of CCL19 and IL-7 treatment leads to a 
dramatic reduction of tumor growth and conﬁrms the impact of chemo-
kines and cytokines in the development of an effective anticancer-im-
munotherapy and the importance of targeting multiple pathways.
